Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving hundreds of leading biopharmaceutical companies globally:

Chubb
Fuji
Citi
Merck
Healthtrust
McKinsey

Generated: September 15, 2019

DrugPatentWatch Database Preview

Details for Patent: 9,187,405

  Try a free trial


See Plans and Pricing

« Back to Dashboard

Which drugs does patent 9,187,405 protect, and when does it expire?

Patent 9,187,405 protects GILENYA and is included in one NDA.

Protection for GILENYA has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has twenty-nine patent family members in twelve countries.

Summary for Patent: 9,187,405
Title:S1P receptor modulators for treating relasping-remitting multiple sclerosis
Abstract: The present invention relates uses of an S1P receptor modulator such as 2-substituted 2-amino-propane-1,3-diol or 2-amino-propanol derivatives, e. g. a compound comprising a group of formula X ##STR00001## for the treatment or prevention of neo-angiogenesis associated with a demyelinating disease, e.g. multiple sclerosis.
Inventor(s): Hiestand; Peter C. (Austria, CH), Schnell; Christian (Hesingue, FR)
Assignee: Novartis AG (Basel, CH)
Application Number:14/257,342
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 9,187,405
Patent Claim Types:
see list of patent claims
Use;

Drugs Protected by US Patent 9,187,405

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Novartis GILENYA fingolimod hydrochloride CAPSULE;ORAL 022527-001 Sep 21, 2010 RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Subscribe to access the full database, or try a Free Trial

Foreign Priority and PCT Information for Patent: 9,187,405

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
United Kingdom0612721.1Jun 27, 2006

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Cipla
Mallinckrodt
UBS
US Army
Argus Health
Chubb

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.